Ligand Pharmaceuticals Incorporated LGND 深 滬
等待開盤 06-25 09:30:00 美东时间
284.91
+5.470
+1.96%
華盛通- 最 高288.46
- 今 開283.35
- 成交量 54.89万股
- 最 低 278.65
- 昨 收 279.44
- 總市值 57.10亿
- 52周最高 288.46
- 市盈率 靜 46.46
- 換手率 2.74%
- 52周最低 112.83
- 委 比 -17.98%
- 總股本 2004.11万
- 歷史最高 288.46
- 量 比 0.64
- 振 幅 3.51%
- 歷史最低 -19.8529
- 每 手 1
- 風險率 33.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ligand prices proposed $550M convertible senior notes offering
Ligand Pharmaceuticals (LGND) said on Monday it plans to offer $550M of convertible senior notes due 2031 in a private placement and expects to grant initial purchasers a 13-day option to buy up to an...
06-22 19:33
Ligand Plans $550M Convertible Notes Offering, To Use Notes Sale for Share Buybacks and Corporate Needs
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers...
06-22 19:14
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Ligand Pharmaceuticals is offering $550 million in convertible senior notes due 2031 in a private placement to qualified institutional buyers. The company also grants initial purchasers a 13-day option to buy up to an additional $82.5 million in notes. Proceeds will be used for convertible note hedge transactions, share repurchases, and general corporate purposes, including potential acquisitions. The notes' interest rate, conversion rate, and ot...
06-22 11:00
As corporate profit margins remain elevated, these mid-caps stand out
With U.S. corporate profit margins remaining near historic highs, investors are increasingly focused on companies that have demonstrated an ability to consistently generate strong earnings and returns...
06-18 21:25
美国银行证券首次覆盖Ligand，给予买入评级目标价244美元
经济观察网 美国银行证券6月10日首次覆盖Ligand Pharmaceuticals Incorporated，给出买入评级及244美元目标价，看好其轻资产高...
06-14 23:10
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
XOMA Royalty Corporation announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Preferred Stock, with dividends of $0.53906 per share for Series A and $0.52344 per depositary share for Series B. The Preferred Stock will be redeemed on July 14, 2026, at $25.00 per share or depositary share. Dividends will be paid on July 15, 2026, to holders of record as of July 2, 2026. The redemption is part ...
06-12 20:05
Ligand Announces 2026 Investor Day in New York City
Ligand Pharmaceuticals will host an Investor Day on December 8, 2026, at the Harvard Club in New York City. The event will feature presentations by Ligand’s senior management on the company’s strategy, investment activity, royalty portfolio, and financial outlook. A live webcast will be available on Ligand’s Investor Relations website. Ligand is a leading royalty aggregator with interests in over 100 biopharmaceutical assets and licenses its prop...
06-10 11:00
Ligand to Participate in June Investor Conferences
Ligand Pharmaceuticals announced that its senior management will participate in two upcoming investor conferences: the Stifel 2026 Boston Cross Sector 1x1 Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Management will engage in one-on-one meetings and a fireside chat during these events. Ligand is a leading royalty aggregator with interests in over 100 biopharmaceutical assets and lice...
05-27 20:01
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
财报速睇 | Ligand Pharmaceuticals Incorporated 2026财年Q1营收0.52亿美元，同比增长14.1%；归母净利润亏损0.13亿美元，同比亏损缩窄68.6%
华盛资讯5月7日讯，Ligand Pharmaceuticals Incorporated公布2026财年Q1业绩，公司Q1营收0.52亿美元，同比增长14.1%，归母净利润亏损0.13亿美元，同比亏损缩窄68.6%。
05-07 19:21
